GADOLIN: Rituximab-Refractory* Patients Who Progressed Early and Had 1-10 Prior Therapies 1
- 95% ECOG PS of 0-1
- 5% ECOG PS of 2
- Median age: 63 (range 34-87)
The follicular lymphoma patients studied in this trial were refractory to rituximab product-containing regimens that primarily included R-CHOP, R-CVP, and rituximab product monotherapy 1,2
Only 2 patients enrolled into the trial had prior
R-CHOP, rituximab product, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone;
R-CVP, rituximab product, cyclophosphamide, vincristine sulfate, and prednisone.
*Rituximab-refractory was defined as patients who had no response to or who progressed within 6 months of therapy.